1 to 6 of 6
Sort by

Web Page
Cancer Immunotherapy Winter School + SITC Clinical Immuno-Oncology Network Workshop

Cancer Immunotherapy Winter School Feb. 22–26, 2021 • Austin, Texas Registration opens soon! ORGANIZERS Christian Capitini, MD – University of Wisconsin-Madison Leisha A. Emens, MD, PhD – UPMC Hillman Cancer Center Daniel Powell, PhD – University of Pennsylvania The Society for...

Library Entry
Understanding Cancer Immunotherapy: Patient Resource Guide - Online Activity

Written with patients and caregivers in mind, this online activity created by the Society for Cancer Immunotherapy expands on what to expect when receiving cancer immunotherapy treatments and how to manage side effects. Based on the Patient Resource Guide, Understanding Cancer Immunotherapy 3...

Library Entry
2017 Cancer Immunology Working Group Town Meeting

The Cancer Immunology Working Group (CIMM) hosted a variety of sessions and events at the AACR Annual Meeting on April 2, 2017. This Cancer Immunology Working Group Town Meeting co-sponsored by CIMM and the Society for Immunotherapy of Cancer (SITC) focused on SITC initiatives and immunotherapy....

SITC Initiatives- Cancer Immunotherapy Biomarkers and Beyond.pdf

IMTAC (Immune Modulatory Therapies for Autoimmunity and Cancer) Summer School in Immunotherapy

Presented by Karolinska Institute in collaboration with the Society for Immunotherapy of Cancer The purpose of this program is to provide PhD students and post-doctoral fellows with seminars and interactive discussions with experts in the field of immunotherapy against cancer. The program is...

 08-28-2017 12:00 - 08-30-2017 14:30 CET

Rational Combinations 360°

Presented by The Conference Forum in collaboration with the Society for Immunotherapy of Cancer With promising cancer immunotherapies in the clinic and an encouraging pipeline of new targets being developed, additional discoveries are now under way to determine the most effective rational...

 06-28-2017 - 06-29-2017
 New York NY

Toxicity Management Workshop

The durable responses and generally well-tolerated side effects characteristic of cancer immunotherapy agents, particularly immune checkpoint inhibitors, have led to an influx of approvals for a growing number of malignancies. However, as more patients turn to immune-based treatments, and as the...

 03-31-2017 | 08:00 - 18:00 ET
 Washington DC